

# Anthoonius de Boer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6934278/publications.pdf>

Version: 2024-02-01

118  
papers

3,793  
citations

172457

29  
h-index

144013

57  
g-index

119  
all docs

119  
docs citations

119  
times ranked

7549  
citing authors

#	ARTICLE	IF	CITATIONS
1	Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37%000 cases. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 820-829.	2.4	7
2	Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study. <i>Europace</i> , 2022, 24, 630-638.	1.7	2
3	Opportunities and Challenges for Decentralized Clinical Trials: European Regulators's™ Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 344-352.	4.7	24
4	Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e33446.	4.3	0
5	Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2333-2340.	2.4	4
6	Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 2794.	3.3	0
7	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3508-3517.	2.4	1
8	Statins After Ischemic Stroke in the Oldest. <i>Stroke</i> , 2021, 52, 1244-1252.	2.0	5
9	Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3588-3598.	2.4	10
10	COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1517-1527.	4.7	12
11	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1703-1715.	1.9	11
12	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. <i>European Journal of Cancer</i> , 2021, 158, 234-245.	2.8	12
13	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	1.2	6
14	Opioid use is associated with increased out-of-hospital cardiac arrest risk among 40,000 cases across two countries. <i>British Journal of Clinical Pharmacology</i> , 2021, . .	2.4	2
15	Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 347-355.	3.0	21
16	Statins After Myocardial Infarction in the Oldest: A Cohort Study in the Clinical Practice Research Datalink Database. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 329-336.	2.6	3
17	The development of a test battery to assess the hand-eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1969-1981.	2.4	9
18	Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 763-770.	2.4	2

#	ARTICLE	IF	CITATIONS
19	Demographics in the 2020sâ€™ Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1899-1903.	2.4	8
20	Effect of CYP3A4*22 and PPAR-Î± Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020, 11, 1068.	2.4	2
21	Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1263-1272.	1.9	2
22	COVIDâ€™19 vaccines: the importance of transparency and factâ€™based education. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2107-2110.	2.4	13
23	Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countries. <i>Europace</i> , 2020, 22, 1206-1215.	1.7	1
24	Developing patientâ€™centric medicines for older people: Reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2008-2013.	2.4	4
25	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 30, 1293-1320.	1.9	3
26	Quality of reporting of drug exposure in pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1141-1150.	1.9	4
27	Realâ€™world outcomes of advanced melanoma patients not represented in phase <sc>III</sc> trials. <i>International Journal of Cancer</i> , 2020, 147, 3461-3470.	5.1	27
28	Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A populationâ€™based nested caseâ€™control study. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1150-1164.	2.4	42
29	The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features. <i>Journal of Clinical Epidemiology</i> , 2020, 126, 193-201.	5.0	11
30	Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a caseâ€™control study. <i>Europace</i> , 2019, 21, 99-105.	1.7	1
31	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1563-1571.	1.9	2
32	Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1355-1362.	4.5	27
33	Measuring the impact of pharmacovigilance activities, challenging but important. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2235-2237.	2.4	14
34	A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. <i>Journal of Clinical Epidemiology</i> , 2019, 114, 60-71.	5.0	6
35	Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1536-1544.	2.1	4
36	Low risk pragmatic trials do not always require participantsâ€™ informed consent. <i>BMJ: British Medical Journal</i> , 2019, 364, l1092.	2.3	28

#	ARTICLE	IF	CITATIONS
37	Cyclooxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 589-600.	1.9	5
38	Risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 623-631.	1.5	7
39	Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the <i>DPYD</i> variant: A matched pair analysis. <i>International Journal of Cancer</i> , 2019, 144, 2347-2354.	5.1	40
40	Effect of <i>CYP4F2</i> , <i>VKORC1</i> , and <i>CYP2C9</i> in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1477-1491.	4.7	23
41	Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. <i>International Journal of Cardiology</i> , 2018, 253, 148-154.	1.7	23
42	Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. <i>Pediatric Diabetes</i> , 2018, 19, 121-128.	2.9	1
43	Undertreatment of hypertension and hypercholesterolaemia in children and adolescents with type 1 diabetes: long-term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 776-785.	2.4	31
44	Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. <i>Pharmacoeconomics</i> , 2018, 36, 359-368.	3.3	67
45	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 222.	2.4	13
46	Commentary on "Gender differences in clinical registration trials; is there a real problem?" by Labots et al. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1639-1640.	2.4	4
47	Effects of age and genetic variations in <i>VKORC1</i> , <i>CYP2C9</i> and <i>CYP3A4</i> on the phenprocoumon dose in pediatric patients. <i>Pharmacogenomics</i> , 2018, 19, 1195-1202.	1.3	2
48	Prescription patterns of angiotensin-converting enzyme inhibitors for various indications: A UK population-based study. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2365-2372.	2.4	24
49	Combined use of polypill components in patients with type 2 diabetes mellitus. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1523-1531.	1.8	8
50	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. <i>BMC Cancer</i> , 2018, 18, 224.	2.6	11
51	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 285-293.	1.9	18
52	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1844-1859.	2.4	17
53	Trends in breast cancer incidence among women with type-2 diabetes in British general practice. <i>Primary Care Diabetes</i> , 2017, 11, 373-382.	1.8	10
54	Defining the noninferiority margin and analysing noninferiority: An overview. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1636-1642.	2.4	113

#	ARTICLE	IF	CITATIONS
55	The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. <i>Quality of Life Research</i> , 2017, 26, 2479-2488.	3.1	22
56	Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. <i>British Journal of Cancer</i> , 2017, 116, 1415-1424.	6.4	94
57	Early life antibiotic use and the risk of asthma and asthma exacerbations in children. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 430-437.	2.6	77
58	Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1835-1843.	2.4	10
59	Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. <i>Trials</i> , 2017, 18, 107.	1.6	56
60	The impact of serum potassium <sup>+</sup> influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: A case-control study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2541-2548.	2.4	8
61	Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. <i>Pharmacogenomics</i> , 2017, 18, 1143-1153.	1.3	5
62	Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 649-654.	2.6	22
63	The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 676-684.	1.9	25
64	<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. <i>Oncologist</i> , 2017, 22, 864-872.	3.7	56
65	Patterns of antiplatelet drug use after a first myocardial infarction during a 10-year period. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 632-641.	2.4	7
66	Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 317-324.	1.9	10
67	Rs895819 in <i>MIR27A</i> improves the predictive value of <i>DPYD</i> variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. <i>International Journal of Cancer</i> , 2016, 138, 2752-2761.	5.1	28
68	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 370-378.	2.4	18
69	Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. <i>Pediatric Diabetes</i> , 2016, 17, 433-440.	2.9	6
70	Case-only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 103-113.	1.9	11
71	A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. <i>Pharmacogenomics</i> , 2016, 17, 583-591.	1.3	9
72	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 714-23.	2.1	40

#	ARTICLE	IF	CITATIONS
73	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. <i>Paediatric Drugs</i> , 2016, 18, 251-260.	3.1	33
74	Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. <i>European Respiratory Journal</i> , 2016, 48, 1063-1073.	6.7	89
75	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 122-131.	1.9	6
76	Organised crime against the academic peer review system. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1012-1017.	2.4	20
77	Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta <sub>2</sub> -agonist use and the risk of myocardial infarction. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 132-141.	1.9	11
78	Digoxin and mortality: lessons for observational studies. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 4-5.	2.4	2
79	Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1647-1659.	2.4	31
80	Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. <i>Pediatric Pulmonology</i> , 2016, 51, 1113-1121.	2.0	11
81	Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. <i>Pediatric Diabetes</i> , 2016, 17, 44-52.	2.9	36
82	Seventeen years of statin pharmacogenetics: a systematic review. <i>Pharmacogenomics</i> , 2016, 17, 163-180.	1.3	52
83	Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 701-708.	1.9	26
84	Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>PLoS ONE</i> , 2015, 10, e0136324.	2.5	25
85	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	1.7	28
86	Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study. <i>Europace</i> , 2015, 17, 753-760.	1.7	13
87	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. <i>Breast Cancer Research</i> , 2015, 17, 100.	5.0	45
88	Increased Mortality by Digoxin in Patients With Atrial Fibrillation?. <i>Journal of the American College of Cardiology</i> , 2015, 65, 220-221.	2.8	0
89	A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. <i>Health Policy</i> , 2015, 119, 195-202.	3.0	29
90	Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 122-131.	5.0	221

#	ARTICLE	IF	CITATIONS
91	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015, 136, 94-100.	1.7	2
92	Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. <i>Annals of Epidemiology</i> , 2015, 25, 590-596.	1.9	15
93	Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. <i>Archives of Disease in Childhood</i> , 2015, 100, 763-768.	1.9	29
94	Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery. <i>JAMA Surgery</i> , 2015, 150, 1126.	4.3	90
95	Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1095-1103.	2.1	16
96	Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. <i>International Journal of Cardiology</i> , 2015, 201, 644-645.	1.7	6
97	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	13.7	562
98	Essential Medicines Are More Available than Other Medicines around the Globe. <i>PLoS ONE</i> , 2014, 9, e87576.	2.5	85
99	Resting Heart Rate Is a Risk Factor for Mortality in Chronic Obstructive Pulmonary Disease, but Not for Exacerbations or Pneumonia. <i>PLoS ONE</i> , 2014, 9, e105152.	2.5	22
100	Selection of Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 32 National Essential Medicines Lists. <i>PLoS ONE</i> , 2014, 9, e106072.	2.5	24
101	Quality of drug label information on QT interval prolongation. <i>International Journal of Risk and Safety in Medicine</i> , 2014, 26, 89-98.	0.6	6
102	Population-Based Cohort Study of Anti-Infective Medication Use before and after the Onset of Type 1 Diabetes in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4666-4674.	3.2	11
103	Pharmacogenomics of oral antiplatelet drugs. <i>Pharmacogenomics</i> , 2014, 15, 509-528.	1.3	10
104	Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling. <i>Drug Discovery Today</i> , 2014, 19, 1294-1297.	6.4	5
105	Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study. <i>PLoS ONE</i> , 2014, 9, e87408.	2.5	4
106	Use of Oral Glucocorticoids and the Risk of Pulmonary Embolism. <i>Chest</i> , 2013, 143, 1337-1342.	0.8	73
107	Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. <i>European Heart Journal</i> , 2013, 34, 1506-1516.	2.2	47
108	When to publish measures of disproportionality derived from spontaneous reporting databases?. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 909-911.	2.4	21

#	ARTICLE	IF	CITATIONS
109	Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 635-642.	1.9	19
110	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. <i>European Heart Journal</i> , 2010, 31, 3046-3053.	2.2	138
111	Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. <i>Drugs</i> , 2010, 70, 2229-2245.	10.9	47
112	Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. <i>Pharmacoepidemiology and Drug Safety</i> , 2008, 17, 1-8.	1.9	37
113	Comparison of different pain scoring systems in critically ill patients in a general ICU. <i>Critical Care</i> , 2008, 12, R15.	5.8	167
114	Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2008, 20, 1093-1097.	1.2	8
115	Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins. <i>Archives of Internal Medicine</i> , 2008, 168, 180.	3.8	127
116	Pharmacogenetics of Glucose-Lowering Drug Treatment. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 291-302.	3.8	22
117	Rate and determinants of 10-year persistence with antihypertensive drugs. <i>Journal of Hypertension</i> , 2005, 23, 2101-2107.	0.5	162
118	Effectiveness of Interventions by Community Pharmacists to Improve Patient Adherence to Chronic Medication: A Systematic Review. <i>Annals of Pharmacotherapy</i> , 2005, 39, 319-328.	1.9	109